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Immunochemical faecal occult blood testing (FIT) provides quantitative test results, which allows optimisation of the cut-off value for
follow-up colonoscopy. We conducted a randomised population-based trial to determine test characteristics of FIT (OC-Sensor
micro, Eiken, Japan) screening at different cut-off levels and compare these with guaiac-based faecal occult blood test (gFOBT)
screening in an average risk population. A representative sample of the Dutch population (n¼10011), aged 50–74 years, was 1:1
randomised before invitation to gFOBT and FIT screening. Colonoscopy was offered to screenees with a positive gFOBT or FIT
(cut-off 50ng haemoglobin/ml). When varying the cut-off level between 50 and 200ngml
 1, the positivity rate of FIT ranged
between 8.1% (95% CI: 7.2–9.1%) and 3.5% (95% CI: 2.9–4.2%), the detection rate of advanced neoplasia ranged between 3.2%
(95% CI: 2.6–3.9%) and 2.1% (95% CI: 1.6–2.6%), and the specificity ranged between 95.5% (95% CI: 94.5–96.3%) and 98.8%
(95% CI: 98.4–99.0%). At a cut-off value of 75ngml
 1, the detection rate was two times higher than with gFOBT screening (gFOBT:
1.2%; FIT: 2.5%; Po0.001), whereas the number needed to scope (NNscope) to find one screenee with advanced neoplasia was
similar (2.2 vs 1.9; P¼0.69). Immunochemical faecal occult blood testing is considerably more effective than gFOBT screening within
the range of tested cut-off values. From our experience, a cut-off value of 75ngml
 1 provided an adequate positivity rate and an
acceptable trade-off between detection rate and NNscope.
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Colorectal cancer (CRC) is a major health problem in the Western
world. Screening can reduce CRC mortality due to detection of
early carcinomas and removal of pre-malignant lesions (Winawer
et al, 1993; Ries et al, 2007). The American Gastroenterology
Association (Winawer et al, 2003), the US Multi-Society Task Force
(Levin et al, 2008), Asia Pacific Working Group on Colorectal
Cancer screening (Sung et al, 2008) and the European council
(Council Recommendation on Cancer Screening, 2003) recom-
mend CRC screening for average risk individuals over 50 years of
age. Several countries have a nation-wide screening programme
mainly based on guaiac-based faecal occult blood test (gFOBT), as
this is the only available test with a proven mortality reduction
(Mandel et al, 1993; Hardcastle et al, 1996; Kronborg et al, 1996),
but consider changing to an immunochemical FOBT (FIT)
programme based on accumulating evidence that FIT is superior
to gFOBT screening, including a higher attendance (Cole et al,
2003; van Rossum et al, 2008; Hol et al, 2008) and detection rate
(Smith et al, 2006; Guittet et al, 2007; van Rossum et al, 2008), as
well as a higher sensitivity without a significant drop in specificity
(Allison et al, 1996, 2007; Wong et al, 2003; Morikawa et al, 2005;
Guittet et al, 2007; Levi et al, 2007). Furthermore, FIT specifically
binds human haemoglobin (Hb), which makes drugs and diet
restrictions superfluous.
Immunochemical faecal occult blood testing samples can be
analysed automatically, which has important advantages for
reproducibility, quality control, capacity, and thus personnel need
and costs (Young et al, 2002; Levi et al, 2007). Another advantage
of FIT is the quantitative test results, which allows determining an
optimal cut-off value for a nation-wide screening programme
(Castiglione et al, 2002; Wong et al, 2003; Guittet et al, 2007;
Levi et al, 2007; Fraser et al, 2008). The cut-off value for a positive
test can be based on a positivity rate that meets the available
colonoscopy resources. At the same time, the number of
colonoscopies is an important determinant of the neoplasia
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screening programme.
Data on positivity rate and test performance at different cut-off
levels of FIT screening in an average risk population are highly
needed to determine the optimal cut-off value for FIT screening.
We, therefore, conducted a randomised trial to compare the
positivity rate, detection rate and specificity of FIT (OC-Sensor
micro; Eiken Chemical Co., Tokyo, Japan) screening at different
cut-off levels with gFOBT (Hemoccult II; Beckman Coulter Inc.,
Fullerton, CA, USA) screening in an average risk screening-naive
population.
MATERIALS AND METHODS
Study population
The study was performed in the Rijnmond region in the southwest
of the Netherlands. This region includes Rotterdam and surround-
ing villages and harbours 338000 inhabitants in the target
population. The region thus combines both rural and urban
settings. Ten thousand and eleven individuals, aged 50–74 years,
were randomly selected from the municipal registries. The selected
individuals were 1:1 randomised per household after stratifying
for age, sex and social economic status into group A (gFOBT) or B
(FIT) using a computer-generated allocation algorithm (Tenalea,
Amsterdam, The Netherlands) (Figure 1). Randomisation occurred
before invitation. Informed consent was asked after randomisa-
tion. Individuals with a history of inflammatory bowel disease or
CRC, a colonoscopy, sigmoidoscopy or barium contrast enema
in the last 3 years, major health problems or inability to sign
informed consent were excluded. Recruitment took place between
November 2006 and November 2007.
Interventions
The randomly selected 10011 individuals were sent a pre-
invitation letter containing information on CRC screening. Two
weeks later, an invitation letter was sent with information on
possible advantages and risks of screening. This was accompanied
by an informed consent form that had to be signed and returned.
A test set was sent along with the invitation. A reminder was sent
6 weeks afterwards to all non-respondents. Information about the
study was further given by direct visits of research physicians to all
general practitioners (GPs) in the region, as well as through a
dedicated website (www.dikkedarmkankerpreventie.nl), mailings
and information sites of the municipality offices, regional news-
papers, and national and regional broadcasting.
Group A: gFOBT
All individuals randomised to gFOBT received three guaiac
imprinted test cards (Hemoccult II) to be used with three
consecutive bowel movements without dietary restrictions or
medication limitations. Participants returned the test kit by mail to
the Gastroenterology and Hepatology laboratory of the Erasmus
University Medical Centre. Tests were analysed without re-
hydration. A test was considered positive if at least one of six
panels was positive. A digital picture of test cards was taken and
stored in a database. As a quality control, 241 (10%) photographs
were re-evaluated by a second technician blinded for the initial test
gFOBT FIT
15011 were randomised 
5004 were invited 
2375 (50%) attended
65 (2.8%) had a
positive screen
62 underwent TC 
206 were excluded 
2351 returned a
complete gFOBT  
24 (1.0%) returned
incomplete gFOBT  
2286 had a negative 
screen 
3 refused TC 
28 (1.2) had an
advanced neoplasia 
4796 were eligible 
5007 were invited 
2979 (62%) attended 
241 (8.1%) had a
positive screen
226 underwent TC
2975 returned a
complete FIT  
4 (0.1%) returned
incomplete FIT
2734 had a negative
screen
15 refused TC 
95 (3.2) had an
advanced neoplasia
4843 were eligible 
2421 did not
participate   
164 were excluded 
1864 did not
participate 
Figure 1 Trial profile. gFOBT: guaiac-based faecal occult blood test; FIT: immunochemical faecal occult blood test; TC: total colonoscopy.
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inter-observer variation.
Group B: immunochemical FOBT
Subjects randomised to FIT screening received one FIT kit
(OC-Sensor micro) to collect a single faecal sample of one bowel
movement without dietary restrictions or medication limitations.
Participants returned the test kit by mail to the same laboratory
that analysed the gFOBT for quantitative analysis using the
automatic OC-Sensor micro instrument. Participants were referred
to colonoscopy at Hb levels above 50ngml
 1.
Follow-up
In case of a negative gFOBT or FIT, both the GP and the
participant were informed by mail within 3 weeks. No further
follow-up was necessary. In case of a positive gFOBT or FIT (faecal
Hb level X50ngml
 1), the GP was informed both by telephone
and mail within 2 weeks. The GP informed the participant about
the test result and referred the participant for colonoscopy. A
colonoscopy was scheduled within 2 weeks after the screening test
results had become available.
Colonoscopy
All colonoscopies were performed in eight hospitals and
performed by experienced endoscopists (individual experience
4200 colonoscopies per annum). The reach of the endoscope in
cm and the location, as well as the adequacy of bowel preparation,
were recorded. During colonoscopy, characteristics, including size,
pedunculated or sessile aspect and location of all polyps, were
noted and recorded. Location was defined as rectum, sigmoid,
descending, transverse, ascending colon or caecum, and was
measured in cm from the anal verge with the endoscope in the
straightened position. Size of each polyp was estimated using an
open biopsy forceps with a span of 7mm. An experienced
gastrointestinal pathologist evaluated all removed polyps. In
accordance with the international classification, CRC was defined
as the invasion of malignant cells beyond the muscularis mucosa.
Patients with intramucosal carcinoma or carcinoma in situ were
classified as having high-grade dysplasia.
Ethical approval
The study was approved by the Dutch Ministry of Health (2006/
02WBO). The approval included the pre-randomisation design.
The study letters and information brochures were approved by the
Institutional Review Board of the Erasmus MC (MEC-2005-264).
Statistical analysis
Differences in proportions between screening strategies were
calculated using a w
2 test. Differences in means between screen-
ing strategies were calculated using a Student’s t-test. All P-values
were two-sided and considered significant if o0.05. Uni- and
multivariate logistic regression analyses were used to determine
the influence of sex and age on positivity rate, number needed to
scope (NNscope), detection rate and number needed to screen
(NNscreen). The positivity rate was defined as the proportion of
participants having a positive gFOBT or FIT test. For FIT, the
positivity rate was separately calculated for cut-off levels of 50, 75,
100, 125, 150, 175 and 200ngml
 1, respectively. The detection rate
was defined as the proportion of participants having advanced
neoplasia. This was calculated as the number of screenees with an
advanced neoplasia divided by all screenees with a complete
screening test. Advanced neoplasia included CRC and advanced
adenoma. Advanced adenoma was defined as adenoma X10mm
or with a histology showing either a X25% villous component or
high-grade dysplasia. We compared faecal Hb measurements
between screenees with a normal colonoscopy and screenees with
non-neoplastic polyps, non-advanced adenomas and advanced
adenomas and CRC as the most advanced lesion by the Kruskal–
Wallis non-parametric analysis of variance and the Mann–
Whitney test, as the data were not normally distributed.
Participation, positivity and detection rate, positive predictive
value (PPV) and specificity were calculated and described as
percentages with 95% confidence intervals (95% CI). The
specificity for advanced neoplasia and CRC was calculated under
the rare disease assumption as the ratio of the number of all
negative screenees and the total number of screenees subtracted by
the number of true positives (Brecht and Robra, 1987). Number
needed to scope describes the number of colonoscopies to find one
screenee with an advanced neoplasia or CRC. Number needed to
screen was calculated as the number of complete screening tests
needed to find one advanced neoplasia or CRC. Differences in PPV
between sexes or age groups in the FIT arm were described for a
cut-off of 100ngml
 1, as this cut-off value is most commonly used
(Castiglione et al, 2002; Vilkin et al, 2005; van Rossum et al, 2008).
RESULTS
In total, 10011 subjects were randomised before invitation to one
of the two FOBTs. Three hundred and seventy (3.7%) subjects were
excluded from analyses (332 subjects met one of the exclusion
criteria, 26 had moved away and 12 had died). A total of 2375 out
of 4796 (50%; 95% CI: 48–51%) participants attended gFOBT
screening. The gFOBT was analysable in 2351 cases (99%). In all,
2979 out of 4843 (62%; 95% CI: 60–63%) subjects attended FIT
screening and the test was complete in 2975 subjects (99.9%)
(Figure 1). The distribution of age (mean±s.d. gFOBT 61±7
years; FIT 61±7 years old) and sex (male gFOBT 46%; FIT 48%) of
the analysable subjects did not differ between the two screening
arms.
Proportion of positive tests
In total, 65 screenees had a positive gFOBT (2.8%; 95% CI: 2.2–
3.6%). Immunochemical faecal occult blood testing was positive in
241 screenees (8.1%; 95% CI: 7.2–9.1%) at a cut-off of 50ngml
 1
and in 103 screenees (3.5%; 95% CI: 2.9–4.2%) at a cut-off of
200ngml
 1 (Table 1). A significant decrease in the proportion of
positive tests was seen between cut-off values of 50 and 75ngml
 1
(8.1 vs 5.7%), followed by a more gradual decrease between cut-off
values of 75 and 200ngml
 1 (Table 1). Male screenees were more
likely to have a positive gFOBT than female screenees (3.7 vs 1.9%;
OR: 1.4; CI: 1.1–1.8) or FIT (FIT
100: 6.8 vs 3.0%; OR: 2.3; 95% CI:
1.6–3.3). The proportion of positive gFOBTs was slightly higher in
screenees aged 60–74 years than in screenees aged 50–59 years,
but this difference was not significant (3.1 vs 2.3%; OR: 1.3; 95%
CI: 0.8–2.2). In the FIT arm, the proportion of positive tests was
significantly higher in screenees aged 60–74 years than in
screenees aged 50–59 years (FIT
100: 6.1 vs 3.3%; OR: 1.8; 95%
CI: 1.3–2.6) (Figure 2).
Colonoscopy findings per test and cut-off value
Sixty-two (95.4%) of the 65 gFOBT-positive screenees and 226
(93.8%) of the 241 screenees with an FIT result X50ngml
 1
underwent a colonoscopy. A double-contrast barium enema was
performed in three subjects with an incomplete colonoscopy. Two
colonoscopies were incomplete due to an obstructing tumour. The
colonoscopy findings are in Table 2 and are related to the amount
of Hb in the faeces. A significantly higher proportion of screenees
with faecal Hb levels of 150–200 (47%) and X200 (61%) had
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50–150ng (25%) (P¼0.009 and Po0.001, respectively), whereas
the proportions were similar among screenees with values of
50–100ngml
 1 and 100–150ngml
 1 (25 vs 18%; P¼0.60).
Haemoglobin levels per finding
The median faecal Hb level of positive screenees with a normal
colonoscopy was 50ngml
 1. Median Hb measurement in screen-
ees with, as the most advanced finding, a non-neoplastic polyp was
94ngml
 1, with a non-advanced adenoma was 112ngml
 1, with
an advanced adenoma was 373ngml
 1 and with a CRC was
404ngml
 1. Faecal Hb levels of screenees with a normal colono-
scopy did not significantly differ from those of screenees with non-
neoplastic (P¼0.88) or non-advanced adenoma (P¼0.89),
whereas the faecal Hb level of screenees with an advanced
adenoma or CRC was significantly higher than that of screenees
with a normal colonoscopy (both Po0.001). The difference in
feacal Hb level between those with advanced adenoma and those
with CRC was not significant (P¼0.53).
Test characteristics
The PPV of gFOBT for advanced neoplasia and for CRC was 45%
(95% CI: 33–58%) and 10% (95% CI: 4–20%), respectively.
Immunochemical faecal occult blood testing showed a more
favourable PPV for detecting advanced neoplasia at higher cut-off
values (Table 1), but this difference was only significant at cut-off
values X175ngml
 1 (gFOBT 45% vs FIT
175 63%; P¼0.029 and
FIT
200 62%; P¼0.035). The PPV for CRC was similar for gFOBT
and FIT at all cut-off levels, although the PPV of FIT steadily
increased with increasing cut-off value (Table 1).
The NNscope to detect one screenee with an advanced neoplasia
or CRC was 2.2 and 10.3, respectively, for gFOBT. The
corresponding numbers with FIT screening were 2.4 and 14.1 at
50ngml
 1 and 1.6 and 8.2 at 200ngml
 1 cut-off values (Table 1)
for advanced neoplasia and CRC, respectively. Men showed a lower
NNscope for advanced neoplasia than women (gFOBT men: 1.8;
women: 3.8; P¼0.04; FIT
100: 1.7; women: 2.5; P¼0.03) (Figure 3).
No differences in NNscope for advanced neoplasia or CRC were
seen between different age groups (gFOBT, P¼0.33; FIT
100,
P¼0.81).
The estimated specificity for not having advanced neoplasia and
CRC was significantly lower for FIT at cut-off values p100ngml
 1
than that for gFOBT (Table 1). Above a cut-off value of
100ngml
 1, the estimated specificity was similar to that of gFOBT.
Detection rate
In the range of tested cut-off levels, FIT detected more advanced
neoplasia than gFOBT (gFOBT: 1.2%; 95% CI: 0.8–1.7%; FIT
50:
3.2%; 95% CI: 2.6–3.9%; FIT
200: 2.1%; 95% CI: 1.6–2.6%), whereas
similar detection rates for CRC were found for gFOBT and FIT
screening.
Male sex was associated with a higher detection rate of advanced
neoplasia in both screening arms (gFOBT: OR 4.2; 95% CI: 1.7–
10.4; FIT
100: OR 3.5; 95% CI: 2.0–6.1). Screenees aged 60–74 years
showed a higher detection rate of advanced neoplasia than
screenees aged 50–59 years in the FIT arm (FIT
100: OR 1.9; 95%
CI: 1.2–3.2), whereas no significant difference between both age
groups was found in the gFOBT arm (OR 1.5; 95% CI: 0.7–3.3).
The NNscreen to find at least one advanced neoplasia was
favourable at all cut-off levels for FIT compared with the gFOBT
arm (Table 1). Male screenees showed significantly lower numbers
needed to screen to detect one advanced neoplasia than female
screenees (gFOBT: men: 57 vs women: 181; P¼0.002; FIT 100
100:
men: 26 vs women: 91; Po0.001).
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We compared FIT screening at different cut-off levels with
conventional gFOBT screening in an average risk screening-naive
population. Our results show that FIT within the complete range
of tested cut-off values (50–200ngml
 1) outperforms gFOBT
screening as it is associated with both higher attendance as well
as higher detection rates of advanced neoplasia, even though
the PPV for detecting advanced neoplasia did not differ
significantly between both tests. The outperformance of FIT over
gFOBT on both attendance and yield is very relevant for the
potential impact of faecal occult blood-based screening on
mortality due to CRC.
Furthermore, FIT testing provides quantitative results, which
allows the determination of an optimal cut-off value for a nation-
wide screening programme based on colonoscopy capacity and the
intended detection rate in the screened population. A low cut-off
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Figure 2 Positivity rate of gFOBT and FIT at different cut-offs in men and women aged 50–59 and 60–74 years.
Table 2 Colonoscopic findings per screenee according to the
haemoglobin levels of the positive FIT
Haemoglobin level in ngml
 1
50–100
n (%)
100–150
n (%)
150–200
n (%)
X200
n (%)
Total screenees 89 (100) 22 (100) 17 (100) 98 (100)
No findings 37 (42) 11 (50) 4 (23) 19 (19)
Non-neoplastic polyp 8 (9) 1 (5) 3 (18) 3 (3)
Non-advanced adenomas 22 (25) 6 (27) 2 (12) 15 (15)
Advanced adenomas 20 (22) 3 (14) 7 (41) 49 (49)
CRC 2 (2) 1 (5) 1 (6) 12 (12)
Advanced neoplasia 22 (25) 4 (18) 8 (47) 61 (61)
CRC¼colorectal cancer; FIT¼immunochemical faecal occult blood test. Advanced
adenoma: adenoma X10mm, villous component (X25% villous) or high-grade
dysplasia; CRC.
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 1) provided not only a high detection rate of
advanced neoplasia, but also more false-positive test results and
thus a higher number of unnecessary colonoscopies. False-positive
results are associated with anxiety (Taylor et al, 2004) and
increased costs (Castiglione et al, 1997). Increasing the cut-off
value resulted in a decrease in detection rate but a more favourable
PPV. The key question is at which cut-off value the magnitude of
benefits (possible the early detection of CRC or the removal of
adenomas) is sufficient to outweigh the harms (burden, complica-
tions, demand on colonoscopy capacity and costs of screening).
The cut-off at which this trade-off becomes acceptable must be
determined in a full cost-effectiveness analysis. However, the ratio
between detection rate and NNscope to find one screenee with an
advanced neoplasia is a good indicator for this trade-off, as it
reflects both benefit (detecting an advanced neoplasia) and harm
(the need to undergo colonoscopy). We found that the NNscope
was higher with FIT than with gFOBT screening when using an FIT
cut-off of 50ngml
 1, but this changed in favour of FIT when
increasing the cut-off to 75ngml
 1 (Table 1). At a cut-off value of
75ngml
 1 , the detection rate with FIT was two-fold higher than
that with gFOBT. At the same time, increasing the FIT cut-off from
50 to 75ngml
 1 had a considerably stronger limiting effect on the
proportion of FIT positives (falling from 8.1 to 5.7%) than any
other similar further increase of the FIT cut-off (Table 1). Further
increasing the cut-off level from 75 to 100ngml
 1 would result in a
larger decline in detection rate (8.8%) than in NNscope (7.3%) and
therefore a less favourable trade-off (Table 1). For these reasons,
we conclude that FIT provided the most optimal trade-off when
using a cut-off value of 75ngml
 1. This conclusion is in agreement
with observations from a colonoscopy study determining the one-
time sensitivity and specificity of the same OC-Micro Latex FIT
test in a population of individuals at higher risk for CRC (Levi
et al, 2007). The latter study and our results come to a lower cut-off
than the recommended cut-off value of 100ngml
 1 by the
manufacturer (Eiken Chemical Co.) and by an earlier study
examining the performance of the OC-Sensor at different cut-off
levels (Castiglione et al, 2000).
Our findings on positivity rate, PPV and the detection rate of
CRC at a cut-off value of 100ngml
 1 are in agreement with those
of other studies using the OC-Sensor with this specific cut-off
(Castiglione et al, 2000, 2002; Grazzini et al, 2004; Dancourt et al,
2008; van Rossum et al, 2008). Both our study and a similarly
designed study by van Rossum et al (2008), however, found a
significantly higher PPV and detection rate for advanced neoplasia
(PPV: 52–53%; DR: 2.4–2.5%) than other studies (PPV: 20–39%;
DR: 0.8–1.2%) (Castiglione et al, 2000, 2002; Grazzini et al, 2004;
Dancourt et al, 2008), even though these studies all focused on the
same age group and applied the same test and definition of
advanced neoplasia. A possible explanation is that both Dutch
studies were carried out in a screening-naive population, whereas
other studies from Italy and France (Castiglione et al, 2000, 2002;
Grazzini et al, 2004; Dancourt et al, 2008) were performed in
parallel to a nation-wide programme and therefore were more
likely to have included subjects screened earlier subjects with a
lower risk on advanced neoplasia.
The positivity rate is the main driver for the number of
colonoscopies among attendants. In countries with a gFOBT
screening programme, changing to FIT screening with a 50ngml
 1
cut-off value would require a considerable (gFOBT: 2.8% vs FIT
50
8.1% positivity rate) increase in colonoscopy capacity for screen-
ing. This effect is augmented by a higher attendance rate to FIT
than to gFOBT screening (van Rossum et al, 2008; Hol et al, 2008).
Thus, FIT screening enables a more efficient screening with
increased participation (Cole et al, 2003; van Rossum et al, 2008;
Hol et al, 2008) and improved test performances (Allison et al,
1996, 2007; Greenberg et al, 2000; Zappa et al, 2001; Smith et al,
2006; Guittet et al, 2007; van Rossum et al, 2008), potentially
allowing a decrease in screening intensity by lengthening the
screening interval.
The detection rate of advanced neoplasia was significantly
higher in men than in women in both screening arms. Likewise,
the NNscreen to detect an advanced neoplasia was lower in men
than in women. Similar differences in detection rates for advanced
neoplasia between both sexes were found in two colonoscopy
screening studies (Lieberman et al, 2000; Schoenfeld et al, 2005;
Regula et al, 2006). Furthermore, the CRC incidence rates are
on an average 1.5 times higher in men than in women aged
50–75 years (Ries et al, 2007; Jemal et al, 2008). Thus, the higher
pre-test probabilities for advanced neoplasia in men explain this
difference. Several studies have, therefore, suggested to develop
sex-specific recommendations for CRC screening (Lieberman,
2005; Brenner et al, 2007). A differentiated approach taking sex
and potentially age into account would be relatively easy with FIT
screening. One could argue to use different cut-off values for men
and women to achieve a similar NNscope, which would result in a
considerable higher cut-off value for women than for men
(Figure 3).
This study was not designed to estimate the sensitivity and
specificity of FOBT, as negative screenees did not undergo a
colonoscopy (golden standard). The aim of this study was to
compare test characteristics of gFOBT and FIT at different cut-off
values. The detection rate and false-positive test results could be
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Figure 3 Numbers needed to scope to find one screenee with an advanced neoplasia in men and women at different cut-off values.
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respectively, as both tests were performed in a similar population.
Specificity for advanced neoplasia of gFOBT and FIT was estimated
under the rare disease assumption based on the number of false-
positive screenees. The specificity can be overestimated if the
number of false negatives increases, which is seen in diseases with
a high prevalence and more sensitive tests (Brecht and Robra,
1987). Therefore, the specificity of advanced adenoma could be
slightly overestimated in both screening arms due to a higher
prevalence. Another limitation of the design of this study is that
the mean Hb levels per lesion (non-neoplastic polyp, non-
advanced adenoma, advanced adenoma or CRC) only pertain to
screenees who had a positive test (faecal Hb level X50ngml
 1)
and subsequently underwent a follow-up colonoscopy. These
results can, therefore, not be generalised to all screenees. However,
this observation could be used for prioritising of colonoscopies in
subjects with a positive test, a topic that can be very relevant in
areas and at time periods of shortage of endoscopic capacity, even
when all subjects with a test result above a chosen cut-off should
undergo endoscopy within a limited time span. Furthermore, this
study describes the first screening round in our population. Data
on PPV and detection rate of successive screening rounds are
needed to provide an insight into the long-term effectiveness of a
population-based screening programme.
In conclusion, this randomised population-based trial provides
important data on the test characteristics of FIT screening at
different cut-off values. Immunochemical faecal occult blood
testing screening is considerably more effective than gFOBT
within the complete range of tested cut-off values. From our
experience, a cut-off value of 75ngml
 1 provided an adequate
positivity rate and an acceptable trade-off between detection rate
and NNscope to find a screenee with an advanced neoplasia.
Increasing the cut-off value can be considered in case of
insufficient colonoscopy capacity, at the cost of a gradual decrease
in detection rate. The optimal cut-off value within a specific
population can be based on a local screening programme, taking
major determinants into account, including the incidence of
neoplasia, the intended screening interval, colonoscopy capacity
and cost efficacy. With this in mind, the use of variable cut-offs for
different sub-groups is a further option for individualised CRC
screening.
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